Please assess the completion status of the following clinical trial:

Trial Title: Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~A patient will be eligible for study participation if all of the following criteria are met:~1. The patient must sign and date the IRB/IEC approved Informed Consent Form/HIPAA Authorization prior to study participation.~2. Patient is at least 18 years of age.~3. If female:~   1. Patient, either male or female, is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with an effective method of birth control acceptable to the Investigator during the study (oral contraceptives, Depo-Provera, intra-uterine device), for at least 1 month prior to enrollment and for 1 month following the completion of the study.~  2. Patient is not breastfeeding.~  3. Patient of childbearing potential must have a negative urine or serum pregnancy test during the screening period.~4. Patient has a diagnosis of low- or intermediate-1 risk MDS, as determined by the International Prognostic Scoring (IPSS) (score of 0-1).~5. Patient must be transfusion dependent (i.e., received ≥ 2 units over an 8-week period prior to registration) or have a hemoglobin value ≤ 10 g/dL on the screening laboratories.~6. Patients must have ≤ 10% blasts in the bone marrow and peripheral blood.~7. Patient must have a platelet counts \> 50,000/microliters and absolute neutrophil counts (ANC) \>500/microliters.~8. Patient must have adequate hepatic and renal functions, defined as serum bilirubin, serum glutamic-oxaloacetic transaminase (SGOT), and serum glutamate pyruvate transaminase (SGPT) ≤ 2 times the upper limit of normal (ULN), and creatinine ≤ 1.5 times the ULN.~9. Patient must have an ECOG score of ≤ 2.~10. The patient has a negative human immunodeficiency virus antibody (HIV) test result.~Exclusion Criteria:~A patient will be ineligible for study participation if any of the following criteria are met:~1. The patient has a history of an allergic reaction or significant sensitivity to Panhematin®.~2. The patient has taken or used any investigational drug or device in the 30 days prior to screening.~3. The patient has chronic myelomonocytic leukemia (CMML).~4. The patient has a history of deep vein thrombosis or known hypercoagulable state.~5. The patient has a history of a pre-existing medical condition that, in the opinion of the investigator, will interfere with the participation in the study.~6. The patient has poor peripheral venous access, if central venous access is not available.~7. The patient has an uncontrolled active infection.~8. The patient has positive test results for hepatitis B surface antigen, and hepatitis C virus antibody.~9. The patient has any other condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panhematin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy